Mostrar el registro sencillo del ítem
dc.contributor | Facultad de Veterinaria | es_ES |
dc.contributor.author | Rodríguez Gil, Alfonso | |
dc.contributor.author | Escamilla Gómez, Virginia | |
dc.contributor.author | Nufer, Melanie | |
dc.contributor.author | Andújar Sánchez, Félix | |
dc.contributor.author | Lopes Ramos, Teresa | |
dc.contributor.author | Bejarano García, José Antonio | |
dc.contributor.author | García Guerrero, Estefanía | |
dc.contributor.author | Calderón Cabrera, Cristina | |
dc.contributor.author | Caballero Velázquez, Teresa | |
dc.contributor.author | García Calderón, Clara Beatriz | |
dc.contributor.author | Hernández Díaz, Paola | |
dc.contributor.author | Reguera Ortega, Juan Luis | |
dc.contributor.author | Rodríguez Torres, Nancy | |
dc.contributor.author | Martínez Cibrián, Nuria | |
dc.contributor.author | Rodríguez Barbosa, José Ignacio | |
dc.contributor.author | Villadiego, Javier | |
dc.contributor.author | Pérez-Simón, José-Antonio | |
dc.contributor.other | Sanidad Animal | es_ES |
dc.date | 2022 | |
dc.date.accessioned | 2024-03-06T12:32:08Z | |
dc.date.available | 2024-03-06T12:32:08Z | |
dc.identifier.citation | Rodríguez-Gil, A., Escamilla-Gómez, V., Nufer, M., Andújar-Sánchez, F., Lopes-Ramos, T., Bejarano-García, J. A., García-Guerrero, E., Calderón-Cabrera, C., Caballero-Velázquez, T., García-Calderón, C. B., Hernández-Díaz, P., Reguera-Ortega, J. L., Rodríguez-Torres, N., Martínez-Cibrián, N., Rodríguez-Barbosa, J. I., Villadiego, J., & Pérez-Simón, J. A. (2022). Combined treatment of graft versus host disease using donor regulatory T cells and ruxolitinib. Scientific Reports, 12(1). https://doi.org/10.1038/S41598-022-12407-X | es_ES |
dc.identifier.other | https://www.nature.com/articles/s41598-022-12407-x | es_ES |
dc.identifier.uri | https://hdl.handle.net/10612/18626 | |
dc.description.abstract | [EN] Donor derived regulatory T lymphocytes and the JAK1/2 kinase inhibitor ruxolitinib are currently being evaluated as therapeutic options in the treatment of chronic graft versus host disease (cGvHD). In this work, we aimed to determine if the combined use of both agents can exert a synergistic effect in the treatment of GvHD. For this purpose, we studied the effect of this combination both in vitro and in a GvHD mouse model. Our results show that ruxolitinib favors the ratio of thymic regulatory T cells to conventional T cells in culture, without affecting the suppressive capacity of these Treg. The combination of ruxolitinib with Treg showed a higher efficacy as compared to each single treatment alone in our GvHD mouse model in terms of GvHD incidence, severity and survival without hampering graft versus leukemia effect. This beneficial effect correlated with the detection in the bone marrow of recipient mice of the infused donor allogeneic Treg after the adoptive transfer. | es_ES |
dc.language | eng | es_ES |
dc.publisher | Nature Research | es_ES |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Sanidad animal | es_ES |
dc.subject.other | T lymphocytes | es_ES |
dc.subject.other | Ruxolitinib | es_ES |
dc.subject.other | Host disease | es_ES |
dc.subject.other | Leukemia | es_ES |
dc.title | Combined treatment of graft versus host disease using donor regulatory T cells and ruxolitinib | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.identifier.doi | 10.1038/S41598-022-12407-X | |
dc.description.peerreviewed | SI | es_ES |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es_ES |
dc.identifier.essn | 2045-2322 | |
dc.journal.title | Scientific Reports | es_ES |
dc.volume.number | 12 | es_ES |
dc.issue.number | 1 | es_ES |
dc.page.initial | 8348 | es_ES |
dc.type.hasVersion | info:eu-repo/semantics/publishedVersion | es_ES |
dc.subject.unesco | 3109 Ciencias Veterinarias | es_ES |
dc.description.project | Tis study is partially funded by Novartis | es_ES |
dc.description.project | The authors thank Dr. João Lacerda for critical reading of the manuscript. This work was supported by grants from Novartis and the Andalusian Regional Government (P18-RT-4047, PI-0052-2018). A.R.G. and J.A.P.S. are members of CIBERONC (CB16/12/00480) and TerCel (16/0011/0035). J.V. is member of CIBERNED (CB06/05/0027). A.R.G. is funded by a Grant of the University of Seville (US-1380874) co-funded by the European Regional Development Fund (ERDF). | es_ES |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
-
Artículos [5503]